Allogene Therapeutics, Inc. ( ALLO) - Key Metrics
ALLO Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0.01 | -$0.13 | -$0.10 | -$0.10 |
| 2026Q1 | $0 | -$0.18 | -$0.05 | -$0.05 |
| 2025Q4 | $0 | -$0.18 | -$0.13 | -$0.13 |
| 2025Q3 | $0 | -$0.19 | -$0.13 | -$0.13 |
| 2025Q2 | $0 | -$0.23 | -$0.18 | -$0.18 |
ALLO Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -4 |
| 2026Q1 | 0% | -3.39 |
| 2025Q4 | 0% | -2.01 |
| 2025Q3 | 0% | -1.63 |
| 2025Q2 | 0% | -1.23 |
ALLO
Price: $2.05
52 week price:
Earnings Per Share: -0.66 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 358933
Market Capitalization: 707.6 million